PD09.07. Impact of Type 2 Diabetes on Outcomes of Neoadjuvant Therapy and Surgery for Esophageal Cancer: A Multi-Center Retrospective Study

Clicks: 21
ID: 325927
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #138 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Surgical Treatment of Esophageal Cancer – early outcomes and complications Background The prognostic impact of type 2 diabetes in esophageal cancer patients receiving neoadjuvant therapy followed by surgery remains unclear. We evaluated its association with perioperative outcomes and long-term survival. Methods We retrospectively analyzed 1,099 patients who underwent neoadjuvant therapy followed by surgery between 2013 and 2024 across three high-volume centers. Type 2 diabetes was defined according to American Diabetes Association criteria. A 1:4 propensity score matching analysis was performed to minimize baseline imbalance. Perioperative outcomes, overall survival (OS), and progression-free survival (PFS) were compared between diabetic and non-diabetic patients. Results After matching, 114 diabetic patients were compared with 456 non-diabetic patients. No significant differences were observed in length of hospital stay, re-operation, re-admission, total complications, or specific postoperative morbidities. After a median follow-up of 1,086 days, 2- and 3-year OS rates were 73.9% vs 77.2% and 62.4% vs 67.8%, respectively (HR 0.84, 95% CI 0.57–1.22, P=0.356). After a median follow-up of 927 days, 2- and 3-year PFS rates were 73.2% vs 65.1% and 65.2% vs 62.4%, respectively (HR 1.13, 95% CI 0.78–1.63, P=0.529). Type 2 diabetes was not associated with inferior survival outcomes. Conclusion Type 2 diabetes was not associated with increased perioperative morbidity or impaired long-term survival following neoadjuvant therapy and surgery.
Reference Key
openalex_W7203988070 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Xipeng Wang, Zhichao Liu, Xuefeng Leng, Xinmin Li, Jingwen Zhang, Xiaoting Yu, Wei Guo, Chengqiang Li, Yongtao Han, Zhigang Li, Hecheng Li, Yuqin Cao
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.146
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.146/70760768/doag077.146.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.